Zenas BioPharma, Inc. Stock-Based Compensation
Zenas BioPharma, Inc. (ZBIO) reported Stock-Based Compensation of $17.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $8.62M, a 42.58% increase year-over-year.
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $9.20M, a 70.72% increase year-over-year.
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.58M, a 37.94% increase year-over-year.
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.34M, a 158.04% increase year-over-year.
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $26.35M, a 143.48% increase from fiscal 2024.
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $10.82M, a 209.61% increase from fiscal 2023.
- Zenas BioPharma, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $3.50M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $17.81M 10-Q · filed 2026-08-13 | $25.39M derived: sum of 3 quarters · filed 2026-08-13 | $32.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.20M 10-Q · filed 2026-05-13 | $16.77M derived: sum of 2 quarters · filed 2026-05-13 | $24.11M derived: sum of 3 quarters · filed 2026-05-13 | $30.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $14.92M derived: sum of 2 quarters · filed 2026-03-16 | $20.96M derived: sum of 3 quarters · filed 2026-08-13 | $26.35M 10-K · filed 2026-03-16 |
| 2025-09-30 | $7.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $13.38M derived: sum of 2 quarters · filed 2026-08-13 | $18.77M 10-Q · filed 2025-11-12 | $24.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $11.43M 10-Q · filed 2026-08-13 | $16.93M derived: sum of 3 quarters · filed 2026-08-13 | $19.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $5.39M 10-Q · filed 2026-05-13 | $10.88M derived: sum of 2 quarters · filed 2026-05-13 | $13.72M derived: sum of 3 quarters · filed 2026-05-13 | $15.26M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.34M derived: sum of 2 quarters · filed 2026-03-16 | $9.87M derived: sum of 3 quarters · filed 2026-03-16 | $10.82M 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.38M derived: sum of 2 quarters · filed 2025-11-12 | $5.33M 10-Q · filed 2025-11-12 | $6.46M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.48M 10-Q · filed 2025-08-12 | $3.62M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $947.00K 10-Q · filed 2025-05-15 | $2.08M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.50M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $2.36M 10-Q · filed 2024-11-12 |